We found that melanoma patients who had a high CD36 expression in the tumors progressed significantly sooner than patients whose expression of CD36 falls in the lower quartile (log-rank test statistics = 3.817, p = 0.05) (Figure 1B). The gene discussed is CD36; the disease is melanoma.